Cerevel Therapeutics, LLC   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Boston MA United States (2018)

Organization Overview

First Clinical Trial
2019
NCT04136873
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Cerevel Therapeutics, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

pf-06649751 (10 trials)

Drugs in Phase 2 Trials (4)

cvl-231 (5 trials)

cvl-865 (4 trials)

cvl-871 (1 trial)

pf-06412562 (1 trial)

Drugs in Phase 1 Trials (6)

alprazolam (xanax) (1 trial)

carbamazepine (tegretol) (1 trial)

carfentanyl (1 trial)

cvl-354 (2 trials)

cvl-936 (1 trial)

ly2795050 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Panic Disorder (Phase 1)

Parkinson Disease (Phase 3)

Schizophrenia (Phase 2)

Seizures (Phase 2)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 11